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Abstract
AIM
To demonstrate the non-inferiority (15% non-inferiority 
limit) of monotherapy with tenofovir disoproxil fumarate 
(TDF) vs  the combination of lamivudine (LAM) plus 
adefovir dipivoxil (ADV) in the maintenance of virologic 
response in patients with chronic hepatitis B (CHB) and 
prior failure with LAM.
METHODS
This study was a Phase IV prospective, randomized, 
open, controlled study with 2 parallel groups (TDF and 
LAM+ADV) of adult patients with hepatitis B e antigen 
(HBeAg)-negative CHB, prior failure with LAM, on 
treatment with LAM+ADV for at least 6 mo, without 
prior resistance to ADV and with an undetectable viral 
load at the start of the study, in 14 Spanish hospitals. 
The follow-up time for each patient was 48 wk after 
randomization, with quarterly visits in which the viral 
load, biochemical and serological parameters, adverse 
effects, adherence to treatment and consumption of 
hospital resources were analysed.
RESULTS
Forty-six patients were evaluated [median age: 
55.4 years (30.2-75.2); 84.8% male], including 22 
patients with TDF and 24 with LAM+ADV. During 
study development, hepatitis B virus DNA (HBV-DNA) 
remained undetectable, all patients remained HBeAg 
negative, and hepatitis B surface antigen (HBsAg) 
positive. Alanine aminotransferase (ALT) values at the 
end of the study were similar in the 2 groups (25.1 
± 7.65, TDF vs  24.22 ± 8.38, LAM+ADV, P  = 0.646). 
No significant changes were observed in creatinine or 
serum phosphorus values in either group. No significant 
differences between the 2 groups were noted in 
the identification of adverse effects (AEs) (53.8%, 
TDF vs  37.5%, LAM+ADV, P  = 0.170), and none of 
the AEs which occurred were serious. Treatment 
adherence was 95.5% and 83.3% in the TDF and the 
LAM+ADV groups, respectively (P  = 0.488). The costs 
associated with hospital resource consumption were 
significantly lower with the TDF treatment than the 
LAM+ADV treatment (€4943 ± 1059 vs  €5811 ± 1538, 
respectively, P  < 0.001).
CONCLUSION
TDF monotherapy proved to be safe and not inferior 
to the LAM+ADV combination therapy in maintaining 
virologic response in patients with CHB and previous 
LAM failure. In addition, the use of TDF generated a 
significant savings in hospital costs.
Key words: Tenofovir; Lamivudine+Adefovir; Efficacy; 
Safety; Adherence; Costs; Hepatitis B
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The Tenosimp-B study was performed to 
demonstrate the non-inferiority (15% non-inferiority 
limit) of tenofovir disoproxil fumarate (TDF) monothe-
rapy versus the combination of lamivudine+adefovir 
(LAM+ADF) in 46 patients with chronic hepatitis B 
(CHB) and resistance to LAM (22 with TDF and 24 with 
LAM+ADV). TDF demonstrated its safety (no significant 
differences in adverse events (AEs), kidney function 
or liver function) and non-inferiority in maintaining 
virologic response [undetectable hepatitis B virus DNA 
(HBV-DNA) and negative for hepatitis B e antigen 
(HBeAg)] during the study, without differences in 
adherence to treatment. Additionally, the use of TDF 
resulted in significant savings in hospital costs.
Rodríguez M, Pascasio JM, Fraga E, Fuentes J, Prieto M, 
Sánchez­Antolín G, Calleja JL, Molina E, García­Buey LM, 
Blanco MÁ, Salmerón J, Bonet ML, Pons JA, González JM, 
Casado MA, Jorquera F; the TENOSIMP­B Research Group. 
Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: 
TENOSIMP­B study. World J Gastroenterol 2017; 23(41): 
7459­7469  Available from: URL: http://www.wjgnet.
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INTRODUCTION
Approximately 400 million people worldwide are 
infected by the hepatitis B virus (HBV)[1]. Given that a 
significant portion of these patients receive treatment 
for management of chronic hepatitis B (CHB) over 
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a long period of time[2-4], it is necessary to use new 
antivirals with potent action and an adequate long-
term safety profile. Likewise, it is important that 
these medications possess a high genetic barrier 
that will lead to reduced HBV resistance rates[5]. The 
establishment of CHB treatment has, as its objective, 
the sustained suppression of virus replication to 
prevent disease progression and increase survival.
Sustained viral suppression with lamivudine 
(LAM) has been shown to reduce the progression of 
the disease, preventing the development of cirrhosis 
and the occurrence of complications, which include 
liver failure, hepatocellular carcinoma and liver-
related mortality[6]. However, while LAM is an effective 
medication, its use has been limited due to the 
development of mutations in the polymerase region of 
HBV that promote resistance, causing loss of antiviral 
activity and its clinical benefit[7]. The rate of appear-
ance of resistance is in the range of 15%-20% per 
year of treatment and may increase to up to 80% at 
5 years after the start of treatment[8]. Management of 
LAM resistance has evolved in recent years. Initially, 
the recommended therapeutic option was to switch 
to adefovir dipivoxil (ADV)[9]. However, it was found 
that this strategy favoured the appearance of ADV 
resistance[10]. One randomized study demonstrated 
that the probability of developing ADV resistance at 3 
years of treatment in patients with resistance to LAM 
was significantly higher in the patient group treated 
with ADV monotherapy than in the group receiving a 
combination of LAM plus ADV[11]. The Clinical Guide-
lines of the European Association for the Study of the 
Liver (EASL) recommend that patients with CHB and 
LAM resistance be changed to tenofovir disoproxil 
fumarate (TDF) or have ADV added if TDF is not 
available[12].
TDF, a prodrug of tenofovir, is a potent nucleotide 
analogue with high efficacy in CHB treatment[13]. Phase 
Ⅲ clinical trials showed that TDF is superior to ADV in 
the suppression of viral replication and in histological 
improvement in both hepatitis B e antigen- (HBeAg-) 
positive and HBeAg-negative patients[5]. Furthermore, 
it is a drug with a high genetic barrier to resistance, 
with no reported cases of resistance during 6 years 
of treatment[14]. Additionally, the antiviral activity of 
TDF is maintained against HBV strains resistant to 
LAM[5,15,16].
The antiviral efficacy of TDF monotherapy has been 
demonstrated in patients with HBV infection and a 
partial prior response to ADV, including patients with 
a history of LAM resistance; its efficacy is similar to 
that of TDF in combination with emtricitabine (FTC) 
[17]. Based on these results and on the fact that, at the 
current time, there are no reports of TDF resistance, 
several authors have purposed TDF monotherapy 
treatment in patients with LAM resistance[12,18].
Patients who have previously failed LAM treatment 
and who have previously received combination treat-
ment with LAM+ADV would be the ideal population 
to determine whether TDF monotherapy is equivalent 
to standard treatment (LAM+ADV) in maintaining a 
virologic response. As a result, the primary objective of 
the TENOSIMP-B study was to demonstrate the non-
inferiority (with a limit of 15%) of TDF monotherapy 
in maintaining an undetectable viral load vs the combi-
nation LAM+ADV treatment in patients with CHB and 
prior failure of LAM. The secondary objectives of the 
study were to compare the safety profiles in each 
treatment group, especially the incidence of renal 
safety; to calculate adherence to treatment; and to 
determine the differences in hospital expenses for 
patients assigned to each of the treatment strategies. 
MATERIALS AND METHODS
TENOSIMP-B is a Phase IV open, randomized, 
controlled study of non-inferiority with 2 parallel arms 
(TDF and LAM+ADV) and prospective follow-up. The 
trial was performed in 14 Spanish public hospitals with 
the participation of adult patients with chronic HBV 
infection. The recruitment period was between August 
2011 and January 2013. Patients were followed for 48 
wk with intermediate visits during weeks 12, 24 and 
36.
During the study period, patients were treated with 
the medication to be studied, and data were collected 
every 12 wk using an electronic case report form 
(eCRF). Variables collected included those related to 
the patient’s clinical data (HBV-DNA load and hepatitis 
B biochemical and serological parameters), information 
on possible adverse events (AEs) during study tracking 
and adherence to therapy using dispensation records 
provided by Hospital Pharmacy Services. In addition, 
through the use of a patient diary, information was 
compiled at each visit regarding the use of hospital 
resources by patients during the study period.
The randomization process was performed in blocks 
to ensure that each centre had a 1:1 ratio of patients 
with TDF (300 mg/d) or LAM (100 mg/d) plus ADV (10 
mg/d). All drugs were administered orally.
The study was authorized by the Medication 
Research Ethics Committee (MREC) of the Hospital 
Universitario Central de Asturias (Oviedo, Asturias, 
Spain), which acted as the reference committee 
in coordination with committees from the other 
participating centres. The study was developed in 
accordance with the ethical principles stated in the 
Declaration of Helsinki and was consistent with the 
guidelines for good clinical practice and the applicable 
local regulatory requirements. All patients gave 
informed written consent for participation in the study.
Study population
Included in the study were patients with HBV infection 
with previous LAM failure who were rescued with 
LAM+ADV, who received this treatment for at least 
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of the AEs, the World Health Organization (WHO) 
recommendations were used. Patients with adverse 
reactions (ARs), that is, AEs related to the studied 
medication, were monitored using the pertinent clinical 
evaluations and laboratory analyses until satisfactory 
resolution of the event or stabilization.  
Adherence: Adherence to treatment was calculated 
using the Morisky-Green test[19] and the dispensation 
records of the Pharmacy Service. The Morisky-Green 
test consists of 4 questions scored as 0 (negative 
response) or 1 (affirmative response). The dispen-
sation records noted, in a retrospective form, the 
quantity of medication dispensed to the patient at 
the prior visit and the units returned to the hospital 
Pharmacy Service following 12 wk of treatment. 
Patients with missing data for these variables were 
considered non-adherent.
The calculation of the percentage of adherence 
to LAM and ADV was performed separately, and the 
lower adherence value was used to determine whether 
the patient was adherent; in these patients, it was 
considered failure to comply if only 1 of the 2 drugs 
used in treatment was taken.
A patient was considered adherent when the 
adherence percentage in the dispensation record was 
greater than or equal to 80% and the score obtained 
from the Morisky-Green test was between 0 and 1.
Analysis of expenses: Hospital resources consumed 
by patients were recorded throughout the 48 wk of 
the study with the objective of quantifying the cost 
in euros associated with the management of these 
patients. The costs calculation was obtained by 
finding the product of resources consumed multiplied 
by the unit cost associated with each resource. 
Unit costs (euros, 2014) of the resources were 
obtained from the healthcare cost database eSalud 
(eHealth)[20]. Pharmaceutical costs were estimated 
based on laboratory sale price (LSP) established in the 
medication catalogue of the General Council of Official 
Associations of Pharmacists[21], applying the deduction 
corresponding to each drug established by Royal 
Decree-Law 8/2010[22].
Statistical analysis
Except for safety analyses, in which the safety 
population was used, statistical analyses were 
performed in the population per protocol (PPP) fun-
ction of statistical software R version 3.10.0[23]. For 
the hypothesis contrasts, an alpha risk of 0.05 was 
assumed. The included P-values were calculated 
based on bilateral contrast without adjustment for the 
performance of multiple contrasts.
For comparison of the percentage of patients 
maintaining a sustained virologic response at 48 wk 
of study and to evaluate differences in AE incidence in 
the 2 arms, Fisher’s exact text was used.
6 mo and with undetectable viral load [HBV-DNA 
below the lower limit of quantification (LOQ)] before 
randomization, with compensated liver disease and 
with positive hepatitis B surface antigen (HBsAg) in the 
baseline visit.
Patients who were co-infected with another virus 
(hepatitis C, hepatitis D or HIV); were intolerant to 
one of the components of the therapeutic regimen; 
had HBV mutations associated with ADV resist-
ance (as evidenced by resistance tests or history 
of virologic rebound reported in the case history); 
had hepatocellular carcinoma; had a liver or kidney 
transplant; had serious pulmonary or neurologic 
disease that might interfere with their participation in 
the study; were pregnant or lactating; were undergoing 
treatment with any experimental (unapproved) 
medications 30 d prior to the baseline visit; and/or had 
moderate to severe renal insufficiency with one of the 
following conditions were not included in this study: a 
glomerular filtration rate (GFR) ≤ 60 mL/min [using 
the abbreviated Modification of Diet in Renal Disease 
(MDRD) formula] and/or creatinine clearance (CrCl) ≤ 
60 mL/min (according to the Cockcroft-Gault equation).
Primary variable: viral load 
The primary variable in this study was the proportion 
of patients who maintained a sustained virologic 
response, defined as HBV-DNA levels that were 
undetectable (below the LOQ) at 48 wk of study using 
the quantitative HBV-DNA detection technique used 
in routine clinical practice in each of the participating 
centres. Additionally, during weeks 12, 24 and 36, the 
following parameters were evaluated: percentage of 
patients with sustained virologic response, percentage 
of patients with virologic rebound in each arm of 
treatment who developed resistance to ADV or 
TDF, percentage of patients with loss of HBsAg and 
percentage of patients with seroconversion to anti-
HBs.
Secondary variables 
During each visit, the patient’s levels of alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), creatinine, CrCl and serum phosphate were 
measured. Other measured parameters included 
safety, using the registry of serious AEs and the 
relationship of AEs to drugs administered in each visit; 
the degree of therapeutic compliance in each group; 
and the costs associated with each treatment group.
Safety: Safety analyses included all patients who 
received at least 1 drug dose during the study and 
all events that occurred during treatment. The safety 
parameters evaluated in this study included all AEs 
and all anomalies (in laboratory parameters) that were 
symptomatic or clinically significant (documented 
as AEs). All AEs were registered in the patient’
s clinical record and in the eCRF. To assess toxicity 
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To evaluate differences in the evolution of hepatic 
and renal function, differences between baseline values 
and those obtained at weeks 12, 24, 36 and 48 were 
compared by hypothesis contrast using the Friedman 
test.
In the cost analysis, differences between costs 
were compared using the Mann-Whitney U test.
RESULTS
Study population
In total, 53 patients were randomized; of these, 4 
patients did not comply with all study selection criteria 
(3 due to moderate or severe renal insufficiency and 
1 due to not having a documented failure on LAM). 
Of the 49 remaining patients, 2 left the study by 
personal petition (1 after the baseline visit and another 
at the week-12 visit) and 1 due to lack of follow-up. 
For the study’s data analysis, the data of 46 patients 
was considered, which constituted the final PPP of the 
study. Of the randomized patients, 22 were assigned 
to the group administered 300 mg TDF/d and 24 
patients were assigned to the group administered 100 
mg LAM/d + 10 mg ADV/d (Figure 1).
The average age of the patients included in the 
analysis was 54.82 ± 11.88 years. Males comprised 
84.8% of the study population. Obesity was present 
in 19.6% of the patients, and 8 patients (17.4%) 
had diabetes or hypertension. Globally, 19.6% of the 
patients had comorbidities in the gastrointestinal, 
cardiovascular or skeletal systems. A small proportion 
of patients (8.7%) had liver cirrhosis (Table 1).
A patient was considered to have LAM resistance 
when, after a negative HBV DNA result was obtained, 
virologic rebound was found without stopping LAM 
administration. All researchers verified the presence 
of LAM resistance in clinical records. In 21.7% of 
patients, LAM resistance was corroborated using a 
resistance test (Table 1).
No significant differences were found between both 
groups of therapy regarding sociodemographic, clinical 
and biochemical characteristics at baseline (Tables 1 
and 2).
Primary variable: viral load
The HBV-DNA viral load remained below the LOQ 
for the length of the study (weeks 12, 24, 26 and 
48) in 100% of patients in both treatment groups. 
As a result, no patient presented virologic rebound 
during the study period. HBeAg remained negative in 
all patients for the duration of the study. No patient 
cleared HBsAg during the 48 wk of the study.
Secondary variables
Safety: Of the 53 patients evaluated in the safety 
analysis, none were found to have a serious AE 
(SAE) during study tracking, nor was there any 
discontinuation in either treatment group due to lack 
of efficacy prior to week 48.
A total of 25 AEs were evaluated during the study 
period; the common cold was the most frequent 
(10.89% of cases). Twenty-three of those cases were 
unrelated events, including 9 in 4 patients from the 
LAM+ADV group and 14 in 9 patients from the TDF 
group. The other 2 AEs occurred in the same patient 
and were considered moderate-intensity adverse 
reactions (RA) and not serious (digestive intolerance 
and muscle pains) (Table 3). In this case, the research 
team decided to discontinue the studied medication 
two weeks after randomization, abating the RA.   
No statistically significant differences between the 
2 study groups were found in the evolution of ALT and 
AST transaminase values (Figure 2), which were used 
to evaluate liver function, from the baseline visit to 48 
wk of study.
With respect to kidney function, no differences 
between the 2 groups were found in phosphorus levels 
(Figure 3), urea, serum creatinine, GFR or CrCl (Figure 
4) at 48 wk of tracking (Table 2). Over the length 
of the study, 4 patients changed to a state of renal 
insufficiency. Two belonging to the LAM+ADV arm 
moved from moderate insufficiency (stage Ⅲ) to mild 
(stage Ⅱ) insufficiency and returned to stage Ⅲ prior 
to the study’s end, and a third changed from stage Ⅱ 
to stage Ⅲ at the final visit. The 4th patient from the 
TDF group moved from stage Ⅱ to stage Ⅲ and back 
to stage Ⅱ prior to the conclusion of the study.
Adherence: Overall, 89.1% of the patients in the 
study were considered adherent, and there was no 
significant difference between the 2 groups concerning 
adherence (TDF 95.5%; LAM+ADV 83.3%; P = 0.745). 
Three patients (1 in the TDF group and 2 in the 
LAM+ADV group) were considered non-adherent due 
to missing values for this variable, although they did 
not present with virologic rebound (their HBV-DNA was 
negative at the end of tracking).
Cost analysis: The total average hospital expense per 
patient treated with TDF and LAM+ADV was €4943 and 
€5811, respectively. These numbers indicate that, in 
patients undergoing TDF treatment, an average savings 
of €868 per patient was observed over the 48 wk of 
the study. The difference in average cost per patient 
between those treated with TDF and those treated with 
LAM+ADV was statistically significant. In concomitant 
medication costs and analytic and diagnostic tests, 
there were no statistically significant differences 
between the 2 treatment groups. Furthermore, there 
were statistically significant differences in drug costs, 
with an average cost savings per TDF patient vs 
LAM+ADV patient of €1252 (Table 4). 
DISCUSSION
LAM, the first nucleoside analogue that has been 
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proven effective against HBV, was widely used during 
the 1990s in CHB treatment. As a consequence of 
its previous use and due to its low genetic barrier 
to resistance, a significant portion of patients with 
CHB who received this treatment have developed 
resistance[8]. For years, the addition of ADV to LAM has 
been the recommended regimen for the management 
of patients with LAM resistance[11]. A retrospective 
multi-centre study analysed the effectiveness of TDF 
monotherapy in patients who had failed treatment with 
LAM and/or ADV, noting a cumulative probability of 
virologic response of 79% after an average treatment 
duration of 23 mo. In this study, it was observed that 
the presence of LAM resistance did not influence the 
response to TDF monotherapy, whereas the presence 
of ADV resistance did influence the response[24]. In 
recent years, various randomized studies have shown 
that TDF monotherapy is as effective as a combined 
treatment with TDF and FTC or entecavir (ETV) in the 
rescue of patients with not only LAM resistance[25,26] 
but also resistance to other analogues such as ADV or 
ETV[27,28].
In the present study, the effectiveness and safety 
of a simplification of the therapeutic regimen consisting 
of TDF monotherapy was evaluated in patients who 
had failed treatment with LAM and who had been 
satisfactorily rescued with a combination of LAM+ADV. 
The simplification with TDF could, at least theoretically, 
encourage adherence to treatment, reduce adverse 
effects over the long term and decrease hospital 
expenses.
In this randomized study, it has been demonstrated 
that TDF monotherapy is as effective as the com-
bination of LAM+ADV in maintaining a complete 
virologic response. During the 48 wk of the study, all 
patients maintained an undetectable HBV-DNA load. 
The preliminary results of a similar study carried out in 
Taiwan showed reappearance of HBV-DNA in 9.4% of 
patients assigned to TDF monotherapy and in 16.7% 
of those assigned to LAM+ADV, although in all cases 
the reappearance of viremia was transitory[29]. Another 
prospective study conducted in China demonstrated 
that TDF monotherapy was superior to a combination 
of LAM+ADV in achieving complete virologic response 
in patients with LAM resistance and suboptimal 
response to LAM+ADV[30]. Finally, a retrospective study 
carried out in the United States evaluated the strategy 
of simplifying treatment to TDF or ETV monotherapy 
in patients who had not completely responded to 
ETV and who had been satisfactorily rescued with 
the ETV+TDF combination[31]. In this study, it was 
observed that virologic rebound rates at 6 mo from the 
start of monotherapy were significantly higher (88%) 
Table 1  Sociodemographic characteristics of the study population n  (%)
Characteristic TDF LAM+ADV Total P  value
(n  = 22) (n  = 24) (n  = 46)
Age - average (range) 53.14 ± 11.95 56.35 ± 11.86 54.82 ± 11.88   0.377
Gender
   Male 17 (77.3) 22 (91.7) 39 (84.4)
   Female 5 (22.7) 2 (8.3) 7 (15.2)
Weight - average (range) 75.37 (46 - 105) 78.72 (62 - 107) 77.08 (46 - 107)   0.663
Height - average (range) 1.68 (1.48 - 1.93) 1.70 (1.56 - 1.80) 1.69 (1.48 - 1.93) 0.30
BMI - average (range) 26.59 (17.10 - 32.96) 27.17 (21.45-34.54) 26.89 (17.1-34.54)   0.883
   < 18.50 - Underweight 2 (9.10) 1 (4.20) 3 (6.50)
   18.50 - 24.99 - Normal 7 (31.80) 8 (33.30) 15 (32.60)
   25.0 - 29.9 - Overweight 9 (40.90) 10 (41.70) 19 (41.30)
   ≥ 30.0 - Obese 4 (18.20) 5 (20.8) 9 (19.60)
LAM resistance establishment   0.725
   Clinical records 18 (81.8) 18 (75.0) 36 (78.3)
   Resistance test 4 (18.2) 6 (25.0) 10 (21.7)
Cirrhosis, F4 state 3 (13.6) 1 (4.2) 4 (8.7)   0.336
Diabetes mellitus and/ or hypertension 2 (9.1) 6 (25.0) 8 (17.4)   0.247




1 patient left the study 
due to lack of tracking
ITT population 
52
2 patients left the study 
due to personal request








Figure 1  Study Population analysed. ADV: Adefovir dipivoxil; LAM: 
Lamivudine; TDF: Tenofovir dipivoxil fumarate; ITT: Intent-to-treat; PP: Per 
protocol.
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in patients who received ETV than in those treated 
with TDF (39%). One of the factors associated in this 
report with the risk of presenting a virologic rebound 
was a duration of complete virologic response of less 
than 12 mo prior to simplification of treatment to 
monotherapy[31]. 
Regarding the biochemical response, in our study, 
we observed that ALT levels at the end of the study 
were similar to baseline levels and that there was 
no difference in ALT levels between patients who 
received monotherapy with TDF and those who 
continued combined treatment with LAM+ADV. On 
the other hand, during the 48 wk of the study, none 
of the patients lost HBsAg, an unsurprising finding 
given the reduced clearance rate of HBsAg in patients 
with HBeAg-negative CHB treated with nucleos(t)ide 
analogues, even when a potent analogue with a high 
generic barrier to resistance, such as TDF, is used[13].
In the safety evaluation, no serious adverse 
effects were observed during the study, and the 
rate of adverse effects was similar in the 2 study 
groups, with the most frequent adverse effect being 
the common cold. A patient from the TDF group 
presented with a drug-related adverse effect (digestive 
intolerance and muscle pains), which resulted in 
the interruption of treatment. As for renal safety, 
although both ADV and TDF can, on rare occasions, 
produce a Fanconi-like renal tubular acidosis, during 
the present study, no significant changes in the levels 
of serum phosphorus were observed in either of the 
2 groups. Regarding kidney function, no differences 
were observed between the baseline visit and the 
end of treatment in either group, nor were there 
differences at the end of the study between patients 
who received TDF and those treated with LAM+ADV. 
Three patients, 2 in the LAM+ADV group and 1 in the 
TDF group, displayed mild and transitory deterioration 
in kidney function during the study, and 1 patient 
belonging to the LAM+ADV group moved from stage 
Ⅱ at the start to stage Ⅲa at the end of the study. 
Table 2  Biochemical parameters: Baseline visit vs  final visit
Baseline visit Visit at 48 wk
TDF LAM+ADV P value TDF LAM+ADV P value
average (range) average (range) average (range) average (range)
AST (UI/mL) 26.66 (9.00-74.00) 26.69 (15.00-69.00) 0.904 26.41 (14.00-71.00) 26.05 (18.00-52.00) 0.916
ALT (UI/mL) 25.41 (12.00-62.00) 23.62 (13.60-40.00) 0.646 26.32 (12.00-55.00) 27.29 (17.00-51.00) 0.965
Phosphorus (mmol/dL) 3.00 (1.80-4.00) 2.84 (1.90-3.80) 0.263 3.08 (1.70-4.40) 2.95 (2.00-3.70) 0.832
Urea (mg/dL) 36.14 (20.00-53.00) 36.96 (18.00-61.90) 0.698 38.29 (25.00-57.00) 38.69 (22.00-53.00) 0.479
Serum creatinine (mg/dL) 0.88 (0.70-1.16) 0.89 (0.60-1.35) 0.912 0.88 (0.69-1.16) 0.92 (0.60-1.27) 0.396
Glomerular filtration rate (mL/min/1.73 m2) 94.13 (66.95-121.03) 97.48 (60.47-157.83) 0.922 93.11 (66.75-123.55) 93.14 (59.14-151.26) 0.468
Creatinine clearance (mL/min) 103.52 (65.57-185.25) 105.43 (64.79-166.22) 0.831 100.85 (60.84-149.66) 102.32 (60.26-157.5) 0.308



























Figure 2  Changes in the transaminases levels: Alanine aminotransferase and aspartate aminotransferase. ADV: Adefovir dipivoxil; LAM: Lamivudine; TDF: 














Figure 3  Changes in the phosphorus levels. ADV: Adefovir dipivoxil; LAM: 
Lamivudine; TDF: Tenofovir dipivoxil fumarate. P value > 0.05 for each visit.
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An observational study conducted in France in 214 
patients who were treated with analogues for a median 
period of 2.4 years showed that kidney function 
decreased significantly in patients treated with ADV in 
monotherapy or combination therapy, whereas kidney 
function remained stable in those treated with LAM, 
TDF or ETV[32]. Although no differences were observed 
between the treatment groups in our study, likely 
due to its short duration and to the limited number of 
patients, it could be inferred that changing from the 
LAM+ADV combination to TDF may be beneficial for 
kidney function over the long term. Additionally, a new 
formulation of tenofovir, tenofovir alafenamide (TAF), 
has shown lower renal toxicity than TDF[33].
Another of the potential beneficial effects of 
treatment simplification may be greater treatment 
adherence. In our study, although adherence was 
greater in the TDF monotherapy group (95.3%) than in 
the combined treatment group (87.5%), the differences 
were not significant. It is possible that with a larger 
number of patients and a longer study period, these 
differences might have reached statistical significance.
Among the most relevant result of this study is the 
significant difference in average overall cost between 
the TDF-monotherapy group and the LAM+ADV 
group due to the reduction in drug costs. This finding 
may have a beneficial impact on the approach to this 
disease from the perspective of the health system.
On the other hand, the main limitations of the 
present study are the small number of patients included 
and the relatively short period of tracking the data. 
Although in randomized studies, there is an 
established preference for analysis of a population 
using intention-to-treat (ITT) vs PPP due to a reduced 
risk of bias; given that our study is a non-inferiority 
study, the more restrictive analysis were chosen 
Table 3  Adverse clinical events at week 48 n  (%)
Event Intensity TDF ( n  = 26) LAM+ADV ( n  = 27) Total (n  = 53) P  value
Adverse reactions 2 (7.70) 0 2 (3.57) 0.236
   Digestive intolerance moderate 1 (3.85) 0 1 (1.89) 1.000
   Muscle pains moderate 1 (3.85) 0 1 (1.89) 1.000
Adverse events 14 (53.85) 9 (37.5) 23 (43.40) 0.17
   Common cold mild 3 (11.54) 2 (7.41) 5 (9.43) 0.699
   Headache mild 1 (3.85) 1 (3.70) 2 (3.77) 1.000
   Retrosternal oppression with heartburn moderate 0 1 (3.70) 1 (1.89) 1.000
   Otitis mild 1 (3.85) 0 1 (1.89) 0.491
   Molar extraction mild 1 (3.85) 0 1 (1.89) 0.491
   Right- and left-flank pain mild 1 (3.85) 0 1 (1.89) 0.491
   Vomiting mild 1 (3.85) 0 1 (1.89) 0.491
   Osteoarticular pain in hands mild 0 1 (3.70) 1 (1.89) 1.000
   Hypophosphatemia and hypomagnesemia moderate 0 1 (3.70) 1 (1.89) 1.000
   Renal colic mild 1 (3.85) 0 1 (1.89) 0.491
   Epigastric pain mild 1 (3.85) 0 1 (1.89) 0.491
   Back pain mild 1 (3.85) 0 1 (1.89) 0.491
   Chronic prostatitis mild 0 1 (3.70) 1 (1.89) 1.000
   Epidermoid carcinoma moderate 1 (3.85) 0 1 (1.89) 0.491
   Vertiginous syndrome mild 0 1 (3.70) 1 (1.89) 1.000
   Itching (eyes, nose and mouth) mild 1 (3.85) 0 1 (1.89) 0.491
   Vertigo mild 0 1 (3.70) 1 (1.89) 1.000
   Choluria mild 1 (3.85) 0 1 (1.89) 0.491



























LAM + ADVCreatinine clearance
Figure 4  Changes in the glomerular filtration rate and creatinine clearance. ADV: Adefovir dipivoxil; LAM: Lamivudine; TDF: Tenofovir dipivoxil fumarate. P value 
> 0.05 for each visit.
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because ITT analysis tends to bias the results towards 
a lack of difference[34]. In this study, patient assignment 
was performed without blinding, a factor that may be 
related to selection bias[34], even though assignment 
without blinding is closer to routine clinical practice.
The results presented here in suggest that treatment 
simplification from the LAM+ADV combination to TDF 
monotherapy, in patients with HBeAg-negative CHB, 
LAM-treatment failure and complete virologic response 
under LAM+ADV treatment, is an efficient strategy. 
The current results are similar to the ones obtained 
with combined treatment in terms of effectiveness and 
safety. The treatment used was shown to decrease 
the cost of management of patients. It is likely that 
this simplification strategy would be equally efficient in 




Approximately 400 million people worldwide are infected by the hepatitis B 
virus. Given that a significant portion of these patients receive treatment for 
management of chronic hepatitis B (CHB) over a long period of time, it is 
necessary to use new antivirals with potent action and an adequate long-
term safety profile. Likewise, it is important that these medications possess 
a high genetic barrier that will lead to reduced HBV resistance rates. The 
establishment of CHB treatment has, as its objective, the sustained suppression 
of virus replication to prevent disease progression and increase survival.
Research frontiers
Tenofovir disoproxil fumarate (TDF), a prodrug of tenofovir, is a potent 
nucleotide analogue with high efficacy in CHB treatment. Phase Ⅲ clinical 
trials showed that TDF is superior to ADV in the suppression of viral replication 
and in histological improvement in both hepatitis B e antigen- (HBeAg-) positive 
and HBeAg-negative patients[5]. 
Innovations and breakthroughs
In this study, it was observed that virologic rebound rates at 6 mo from the start 
of monotherapy were significantly higher (88%) in patients who received ETV 
than in those treated with TDF (39%). One of the factors associated in this 
report with the risk of presenting a virologic rebound was a duration of complete 
virologic response of less than 12 mo prior to simplification of treatment to 
monotherapy.
Applications
The treatment used was shown to decrease the cost of management of 
patients. It is likely that this simplification strategy would be equally efficient in 
patients with the same characteristics who are under LAM+TDF treatment.
Peer-review
This study focused on the efficacy and safety of Tenofovir disoproxil fumarate 
versus Lamivudine + adefovir in patients with chronic hepatitis B with prior 
failure with Lamivudine.
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P value
(n  = 22) (n  = 24)
Studied medication 2966 (69) 4218 (558) -1252 < 0.0011
Concomitant medication 218 (599) 82 (213) 136 0.484
Medical visits 505 (158) 500 (137)     5 0.942
Tests 1388 (182) 1363 (242)     25 0.834
Admissions and surgeries 0 (0) 0 (0) 0 (0) NA
Total 4943 (1059) 5811 (1538) -868 < 0.0011
1Statistically significant difference. ADV: Adefovir dipivoxil; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; LAM: Lamivudine; TDF: 
Tenofovir dipivoxil fumarate.
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